Allogene Therapeutics, Inc. (ALLO) Stock

Allogene Therapeutics, Inc. (ALLO) is a Healthcare stock trading at $1.99 (as of 2026-06-18), with a market capitalization of $690.31M and a trailing P/E of -2.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer, including CAR T and related product candidates. Its pipeline includes UCART19 and multiple allogeneic CAR T programs targeting CD19 and other antigens, aimed at treating patients across settings such as B-cell ALL and non-Hodgkin lymphoma, with additional candidates in trials for multiple myeloma and other malignancies.

Valuation — source: SEC EDGAR (first-party)
Price	$1.99
Market Cap	$690.31M
P/E Ratio	-2.5
EV / EBITDA	-3.5
Price / Book	2.35
DCF Value (model)	$-10.20
DCF Upside vs Price	-612.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-62.3%
Current Ratio	9.65
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-34.1%
FCF Growth (YoY)	-25.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-5.42 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-111.8%
vs Industry	-114.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Pfizer Inc ($49.79M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	David D. Chang
Employees	226
Country	US
IPO Date	2018-10-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.